Published in Haematologica on December 01, 2014
BPTF promotes tumor growth and predicts poor prognosis in lung adenocarcinomas. Oncotarget (2015) 0.83
GPX3 promoter is methylated in chronic myeloid leukemia. Int J Clin Exp Pathol (2015) 0.78
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget (2016) 0.77
Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia. PLoS One (2017) 0.75
Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis. Oncotarget (2016) 0.75
Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin. Leukemia (2016) 0.75
Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy. Oncotarget (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
High-resolution profiling of histone methylations in the human genome. Cell (2007) 85.74
Chromatin modifications and their function. Cell (2007) 55.98
DNA methylation patterns and epigenetic memory. Genes Dev (2002) 33.83
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (2009) 32.97
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet (2007) 32.41
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
CpG-rich islands and the function of DNA methylation. Nature (1986) 24.90
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature (2010) 18.63
Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature (2000) 18.26
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature (2003) 14.35
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science (2011) 14.29
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci (2006) 13.32
Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science (2011) 13.16
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature (2003) 12.06
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet (2009) 10.54
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol (2002) 9.83
Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature (2010) 9.81
Role of histone H2A ubiquitination in Polycomb silencing. Nature (2004) 9.48
Increased methylation variation in epigenetic domains across cancer types. Nat Genet (2011) 8.92
Suppression of inflammation by a synthetic histone mimic. Nature (2010) 8.80
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Regulation of chromatin by histone modifications. Cell Res (2011) 8.44
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Cancer epigenetics: from mechanism to therapy. Cell (2012) 7.74
Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet (1998) 7.52
Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem (2007) 7.49
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet (2011) 6.98
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature (2014) 6.83
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics (2008) 6.45
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell (2005) 6.29
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell (2004) 5.98
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2010) 5.62
New nomenclature for chromatin-modifying enzymes. Cell (2007) 5.34
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature (2010) 5.23
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell (2010) 4.99
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet (2011) 4.85
The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res (1999) 4.74
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol (2010) 4.72
Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol Cell (2010) 4.69
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature (2009) 4.60
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
CpG islands--'a rough guide'. FEBS Lett (2009) 4.55
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 4.52
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia (2011) 4.28
Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev Genet (2011) 4.25
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature (2012) 4.08
Rethinking how DNA methylation patterns are maintained. Nat Rev Genet (2009) 4.03
Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol (2004) 4.00
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia (2013) 3.93
Array-based genomic resequencing of human leukemia. Oncogene (2010) 3.77
Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol (2008) 3.74
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell (2005) 3.70
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol (2010) 3.38
Structure and E3-ligase activity of the Ring-Ring complex of polycomb proteins Bmi1 and Ring1b. EMBO J (2006) 3.21
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol (2011) 3.17
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol (2012) 3.15
Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature (2009) 3.13
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med (2012) 3.03